

12 June 2024

**Scancell Holdings plc**  
("Scancell" or the "Company")

**Scancell Signs Agreement with Major International Biotechnology Company to Evaluate an Antibody in the Glymab® Portfolio**

*Exclusivity has been granted to evaluate anti-glycan monoclonal antibody generated via Scancell's proprietary GlyMab® platform.*

**Scancell Holdings plc (AIM: SCLP)**, the developer of novel oncology immunotherapies today announces a major international biotechnology company will exclusively evaluate a Scancell investigational anti-glycan monoclonal antibody for development of novel therapeutic products. Under the terms of the agreement, Scancell has granted the company seven months exclusivity for evaluation, which includes an \$1M exclusivity payment payable within 30 days.

**Professor Lindy Durrant, Chief Executive Officer of Scancell, said:** *"We are very pleased to announce this agreement today with a leading international biotechnology company. This is now the second anti-glycan monoclonal antibody generated via our proprietary GlyMab® platform to be evaluated, the first now being developed under a commercial licence agreement. This provides further validation of the potential of our antibody platform to create novel, differentiated antibody products. Whilst the agreement is for an initial exclusive evaluation period, there is an option to licence, and we look forward to providing the market with any updates in due course."*

The Scancell anti-glycan monoclonal antibody is a humanised antibody developed by Scancell, using its novel anti-cancer GlyMab® platform. This is one of five monoclonal antibodies currently in Scancell's antibody portfolio which provides a rich reservoir of potential products for its in-house clinical development and also for further deals.

**About GlyMab®**

Scancell is building a pipeline of differentiated anti-cancer monoclonal antibodies ('mAbs') that target sugar motifs rather than proteins. The Company currently has five novel mAbs in early-stage development and has the potential to use its unique methodology to identify many more mAbs against glycan targets in the future. All cells are covered by a dense layer of sugar structures, called glycans, which change when a normal cell turns into a cancer cell. These glycan motifs that are associated with tumour malignancies can be targeted by antibodies such as the Company's GlyMab® portfolio. A robust portfolio of patents and applications, as well as know-how, surround the GlyMab® platform and generated drug candidates. The GlyMab® technology is part of Scancell's antibody portfolio, joining AvidiMab®, a technology that can be applied to all antibodies (regardless of the technology used to generate them), enhancing their potency and ability to directly kill tumour cells.

**This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).**

**-ENDS-**

**For further information, please contact:**

**Scancell Holdings plc** +44 (0) 20 3709 5700  
Professor Lindy Durrant, CEO  
Dr Jean-Michel Cosséry, Non-Executive Chairman

**Stifel Nicolaus Europe Limited** (Nominated Adviser and Joint Broker  
Nicholas Moore/Samira Essebiyea/Ben Good (Healthcare Investment Banking)  
Nick Harland (Corporate Broking)) +44 (0) 20 7710 7600

**WGPartners LLP (Joint Broker)** +44 (0) 20 3705 9330  
David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

**Panmure Gordon (UK) Limited** (Joint Broker) +44 (0) 20 7886 2500  
Freddy Crossley/Emma Earl (Corporate Finance)  
Rupert Dearden (Corporate Broking)

**ICR Consilium** +44 (0) 20 3709 5700  
Mary-Jane Elliott/ Angela Gray/ Lindsey Neville  
[scancell@consilium-comms.com](mailto:scancell@consilium-comms.com)

## About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).

For further information about Scancell, please visit: <https://www.scancell.co.uk/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

AGRUUONRSAUNARR